Innate Pharma (FRA:IDDA) Institutional Ownership : 0.13% (As of May. 18, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innate Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Innate Pharma's institutional ownership is 0.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Innate Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Innate Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

Innate Pharma Institutional Ownership Historical Data

The historical data trend for Innate Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Institutional Ownership Chart

Innate Pharma Historical Data

The historical data trend for Innate Pharma can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.07	0.06	0.06	0.05	0.08	0.08	0.08	0.08	0.09	0.13

Innate Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Innate Pharma (FRA:IDDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDDA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IPH:France

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (FRA:IDDA) Headlines

No Headlines